{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:52:01Z","timestamp":1793721121337,"version":"4.6.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The lack of agreement and knowledge of optimal endpoints in cachexia trials have impeded progress in finding interventions counteracting the devastating effects cancer cachexia has on morbidity and mortality. An endpoint should both be sensitive enough to detect change and specific enough not to be influenced by other conditions or treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>There is a wealth of potential and applied endpoints in trials investigating cachexia. As of today, there is no generally acknowledged consensus, but assessments of key factors such as body composition should continue to be applied. However, the impact and effect size necessary to achieve clinical benefit using these endpoints are not clear. Further, the use of other endpoints assessing physical function, symptom evaluation and quality of life remains to be elucidated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>It is essential that endpoints are clinically relevant and further research is therefore needed to develop endpoints that are meaningful for patients with cachexia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000387","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T21:54:28Z","timestamp":1538776468000},"page":"445-452","source":"Crossref","is-referenced-by-count":21,"title":["Endpoints in clinical trials in cancer cachexia: where to start?"],"prefix":"10.1097","volume":"12","author":[{"given":"Barry J.A.","family":"Laird","sequence":"first","affiliation":[{"name":"Institute of Genetics and Molecular Medicine, University of Edinburgh"},{"name":"St Columba's Hospice, Edinburgh, UK"},{"name":"European Palliative Care Research Centre (PRC), Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU \u2013 Norwegian University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trude R.","family":"Balstad","sequence":"additional","affiliation":[{"name":"European Palliative Care Research Centre (PRC), Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU \u2013 Norwegian University of Science and Technology"},{"name":"Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tora S.","family":"Solheim","sequence":"additional","affiliation":[{"name":"European Palliative Care Research Centre (PRC), Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU \u2013 Norwegian University of Science and Technology"},{"name":"Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230926","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with nonsmall-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"key":"R2-20230926","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"},{"key":"R3-20230926","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol"},{"key":"R4-20230926","doi-asserted-by":"crossref","first-page":"9618","DOI":"10.1200\/jco.2014.32.15_suppl.9618","article-title":"Enobosarm and lean body mass in patients with nonsmall cell lung cancer","volume":"32","author":"Crawford","year":"2014","journal-title":"J Clin Oncol"},{"key":"R5-20230926","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","article-title":"Cachexia: pathophysiology and clinical relevance","volume":"83","author":"Morley","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"R6-20230926","doi-asserted-by":"crossref","first-page":"e000097","DOI":"10.1136\/bmjgast-2016-000097","article-title":"Cachexia in cancer: what is in the definition?","volume":"3","author":"Vanhoutte","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"R7-20230926","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"R8-20230926","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s13539-011-0027-5","article-title":"The cachexia score (CASCO): a new tool for staging cachectic cancer patients","volume":"2","author":"Argiles","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R9-20230926","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0148607108325076","article-title":"Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group","volume":"33","author":"Bozzetti","year":"2009","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R10-20230926","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"R11-20230926","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ajcn\/83.6.1345","article-title":"Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis","volume":"83","author":"Fearon","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"R12-20230926","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jcsm.12083","article-title":"Request for regulatory guidance for cancer cachexia intervention trials","volume":"6","author":"Fearon","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R13-20230926","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/jcsm.12206","article-title":"Muscle mass and association to quality of life in nonsmall cell lung cancer patients","volume":"8","author":"Bye","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R14-20230926","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/s12885-017-3562-4","article-title":"Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced nonsmall-cell lung cancer","volume":"17","author":"Naito","year":"2017","journal-title":"BMC Cancer"},{"key":"R16-20230926","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","article-title":"Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib +\/- megestrol acetate for patients with cancer-related anorexia\/cachexia syndrome","volume":"31","author":"Madeddu","year":"2012","journal-title":"Clin Nutr"},{"key":"R17-20230926","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr"},{"key":"R18-20230926","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2014.56.1894","article-title":"Diagnostic criteria for the classification of cancer-associated weight loss","volume":"33","author":"Martin","year":"2015","journal-title":"J Clin Oncol"},{"key":"R19-20230926","doi-asserted-by":"crossref","first-page":"e0169136","DOI":"10.1371\/journal.pone.0169136","article-title":"Prognostic impact of CT-quantified muscle and fat distribution before and after first-line-chemotherapy in lung cancer patients","volume":"12","author":"Nattenmuller","year":"2017","journal-title":"PLoS One"},{"key":"R20-20230926","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/0284186X.2012.724536","article-title":"Nonsteroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review","volume":"52","author":"Solheim","year":"2013","journal-title":"Acta Oncol"},{"key":"R21-20230926","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1002\/cncr.27430","article-title":"Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study","volume":"118","author":"Hiura","year":"2012","journal-title":"Cancer"},{"key":"R22-20230926","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.bjc.6604148","article-title":"Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia\/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study","volume":"98","author":"Strasser","year":"2008","journal-title":"Br J Cancer"},{"key":"R23-20230926","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","article-title":"ROMANA: 3 a phase 3 safety extension study of anamorelin in advanced nonsmall-cell lung cancer (NSCLC) patients with cachexia","volume":"28","author":"Currow","year":"2017","journal-title":"Ann Oncol"},{"issue":"(Suppl 2)","key":"R24-20230926","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/sj.ejcn.1601426","article-title":"Selection of methodology to assess food intake","volume":"56","author":"Biro","year":"2002","journal-title":"Eur J Clin Nutr"},{"key":"R25-20230926","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jpainsymman.2008.01.011","article-title":"A first step in the development of an international self-report instrument for physical functioning in palliative cancer care: a systematic literature review and an expert opinion evaluation study","volume":"37","author":"Helbostad","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"R26-20230926","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2407-13-135","article-title":"Functional capacity, physical activity and muscle strength assessment of individuals with nonsmall cell lung cancer: a systematic review of instruments and their measurement properties","volume":"13","author":"Granger","year":"2013","journal-title":"BMC Cancer"},{"key":"R27-20230926","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jcsm.12201","article-title":"A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer","volume":"8","author":"Solheim","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R28-20230926","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clnu.2010.09.010","article-title":"Hand grip strength: outcome predictor and marker of nutritional status","volume":"30","author":"Norman","year":"2011","journal-title":"Clin Nutr"},{"key":"R29-20230926","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1080\/0284186X.2016.1219047","article-title":"Physical performance measures for predicting outcome in cancer patients: a systematic review","volume":"55","author":"Verweij","year":"2016","journal-title":"Acta Oncol"},{"key":"R30-20230926","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/0269216315588743","article-title":"A systematic review and thematic synthesis of quality of life in the informal carers of cancer patients with cachexia","volume":"30","author":"Wheelwright","year":"2016","journal-title":"Palliat Med"},{"key":"R31-20230926","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jpainsymman.2016.09.010","article-title":"Development of the EORTC QLQ-CAX24, A Questionnaire for cancer patients with cachexia","volume":"53","author":"Wheelwright","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"R32-20230926","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.critrevonc.2015.12.008","article-title":"Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: a systematic review","volume":"99","author":"Tarricone","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"R33-20230926","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00520-017-4022-z","article-title":"A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer","volume":"26","author":"Vagnildhaug","year":"2018","journal-title":"Support Care Cancer"},{"key":"R34-20230926","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ctrv.2013.11.007","article-title":"Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score","volume":"40","author":"Douglas","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"R35-20230926","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ejca.2008.02.033","article-title":"Cancer cachexia: developing multimodal therapy for a multidimensional problem","volume":"44","author":"Fearon","year":"2008","journal-title":"Eur J Cancer"},{"key":"R36-20230926","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/MCO.0b013e3283455d45","article-title":"Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity","volume":"14","author":"Prado","year":"2011","journal-title":"Curr Opin Clin Nutr Metab Care"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201812000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T07:16:07Z","timestamp":1695712567000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201812000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000387","relation":{},"ISSN":["1751-4258","1751-4266"],"issn-type":[{"value":"1751-4258","type":"print"},{"value":"1751-4266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}